Person:
KISKAÇ, MUHARREM

Profile Picture
Google ScholarScopusORCIDPublons
Status
Kurumdan Ayrılmıştır.
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
MUHARREM
Last Name
KISKAÇ
Name
Email Address
Birth Date

Filters

Browse subject tree
20141
Reset filters

Settings

Author: Karatoprak, CUMALİ × Subject: type 2 diabetes ×

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    PublicationOpen Access
    Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients
    (2014-01-01) Cakirca, MUSTAFA; Soysal, Pinar; Zorlu, MEHMET; Kiskac, MUHARREM; Kanat, Mustafa; CIKRIKCIOGLU, Mehmet Ali; Karatoprak, CUMALİ; HURSITOGLU, Mehmet; Camli, AHMET ADİL; ERKOC, Reha; ABDUL-GHANI, Muhammad; ÇAKIRCA, MUSTAFA; KARATOPRAK, CUMALİ; ZORLU, MEHMET; KISKAÇ, MUHARREM; SOYSAL, PINAR; ÇAMLI, AHMET ADİL
    Aims: A close association has been demonstrated between increased cardiovascular risk and high asymmetric dimethylarginine (ADMA) levels in type 2 diabetes mellitus (DM) patients. We planned to measure serum ADMA levels in type 2 DM patients using vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Materials and methods: A total of 68 type 2 DM patients who were on metformin were enrolled in the study. Based on the glycemic levels of patients, vildagliptin was added on to treatment in 33 patients. Patients were followed for 6 months. Serum ADMA, C-reactive protein, and fibrinogen levels were compared in groups of patients using metformin or metformin + vildagliptin, after 6 months. Results: Serum ADMA levels were found to be significantly lower in the group using vildagliptin compared to the group using metformin + vildagliptin (P<0.001). However, serum C-reactive protein and fibrinogen levels were statistically similar in the two study groups (P=0.34 and P=0.23, respectively). Conclusion: Metformin + vildagliptin treatment was observed to lower serum ADMA levels in type 2 DM patients. Our findings notwithstanding, large-scale prospective randomized controlled studies are warranted to conclude that vildagliptin provides cardiovascular protection along with diabetes regulation. Keywords: asymmetric dimethylarginine (ADMA); dipeptidyl peptidase-4 (DPP-4) inhibitor; type 2 diabetes mellitus; vildagliptin.